CBD supplements still face an authorisation gap
As of ACSA's update on 21 September 2026, the European Union had granted no novel-food authorisations for cannabinoids. A favourable EFSA assessment published that month concerned a particular synthetic CBD product, with specified composition and proposed conditions of use. European Commission authorisation remained a separate step. This is the immediate answer for products marketed as CBD food supplements: a scientific assessment of one formulation does not make the entire category an authorised food market.
Seed ingredients are a different food category
Hemp seeds, seed oil and ground seed flour have an established food-use history in the EU, according to ACSA. They contribute ordinary nutritional components and have their own ingredient identities. Isolated cannabinoids, concentrated extracts and cannabinoids added to food fall into the novel-food framework. A bottle described simply as hemp oil can therefore leave an important compositional distinction unresolved: oil made from seeds and an oil containing added CBD are different formulations with different regulatory questions.
The 2026 assessment was specific
ACSA explains that EFSA's favourable assessment concerned synthetic CBD of at least 98% purity dissolved in medium-chain triglyceride oil. Its conclusions applied to the assessed conditions and an adult population aged 25 or older, excluding pregnancy, breastfeeding and people taking medicines. Broader uncertainties remain concerning long-term effects on the liver, neurological function and reproductive and immune systems. CBD can also interact with enzymes involved in drug metabolism. These details explain why the identity of the formulation and the population studied matter to a safety conclusion.
A medicine has a defined clinical use
Epidyolex is an authorised cannabidiol medicine with defined epilepsy indications, including Lennox–Gastaut and Dravet syndromes in combination with clobazam, and tuberous sclerosis complex with other epilepsy treatments, in patients aged two years or older. Its authorisation is based on a pharmaceutical product and clinical evidence for those uses. The European Medicines Agency also describes adverse effects and liver-related monitoring. That system ties composition, indication, clinical evidence and surveillance together, rather than treating CBD as a general-purpose wellness ingredient.
Evidence depends on the condition
Evidence for one medicine and condition does not establish benefits for unrelated symptoms. A small 2024 placebo-controlled pilot trial involving 30 people with insomnia found that CBD and placebo produced similar results on most sleep outcomes. This contrasts with the specific epilepsy evidence behind an authorised medicine. Reliability therefore has several concrete components: the product's composition, its legal category, evidence for the intended condition and the safety needs of the person using it. The word supplement supplies none of those clinical findings by itself.
Sources & further reading
General information, not individual legal or medical advice.